Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017242 | 1.00 | CHRM1 (0.58) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13300984 | 1.00 | CHRM1 (0.58) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL10569051 | 0.89 | CHRM1 (0.47) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL12674256 | 0.85 | CHRM1 (0.43) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9097759 | 0.83 | CHRM1 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13038562 | 0.83 | CHRM1 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL11849760 | 0.80 | CHRM1 (0.54) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Oxalic Acid SCHEMBL10569543 | 0.80 | CHRM1 (0.51) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9289352 | 0.79 | CHRM2 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL96686 | 0.79 | CHRM2 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180078536-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2018-03-22 | — | — | US | disclosed |
| US-9849117-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2017-12-26 | — | — | US | disclosed |
| US-20170112814-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-9567343-B2 | Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-20150183794-A1 | AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-8236803-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8044198-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090054446-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG | 2009-02-26 | — | — | US | disclosed |
| US-5508405-A | CHOLINERGIC AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1996-04-16 | — | — | US | disclosed |
| US-5451587-A | 3-(2-PROPYNYLOXY)-1-AZABICYCLO(2.2.2)OCTANE FOR TREATING ALZHEIMER*S DISEASE | BOEHRINGER INGELHEIM GMBH (DE) | 1995-09-19 | — | — | US | disclosed |
| US-5286864-A | Deprotonation and salt formation with sodium hydride; alkylation, deprotecting | BOEHRINGER INGELHEIM KG (DE) | 1994-02-15 | — | — | US | disclosed |
| EP-0370415-B1 | QUINUCLIDINES, THEIR PHARMACEUTICAL USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM KG (DE) | 1993-06-02 | — | — | EP | disclosed |
| EP-0370415-A1 | Quinuclidines, their pharmaceutical use and process for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1990-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183794-A1 | AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 19/4885CHRM2 21/4885CHRM4 20/4885 |
| US-20170112814-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 18/4885CHRM2 21/4885CHRM4 20/4885 |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | CHRM1 4409/4885CHRM2 4269/4885CHRM4 4418/4885 |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | CHRM1 2200/4885CHRM2 1932/4885CHRM4 1364/4885 |
| US-20180078536-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 18/4885CHRM2 21/4885CHRM4 20/4885 |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHRM1 3638/4885CHRM2 4042/4885CHRM4 3791/4885 |
| US-20090054446-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRM1 18/4885CHRM2 21/4885CHRM4 20/4885 |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHRM1 3780/4885CHRM2 4407/4885CHRM4 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.